AC Immune SA
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving AC Immune SA now
Current reporting with the operating signal separated from the noise.
AC Immune SA: AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease
The story matters when it changes AC Immune SA’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference
The story matters when it changes AC Immune SA’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.AC IMMUNE SA Earnings Results: $ACIU Reports Quarterly Earnings
Investors are testing whether AC Immune SA’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest ACIU filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
AC Immune SA, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →